HHS lays groundwork for new FDA rule on releasing the CRLs

FDA halts release of new drug rejection letters while working to formalize policy

The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has learned, following a citizen’s petition from an unnamed pharma compan | The FDA has paused…